Ovarian CancerOLIVIANCT07167433
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
An observational study of Ovarian Cancer, run by AstraZeneca at 14 sites in Brazil.
Trial summary
The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Cancer
- How many people
- 256 participants
- Where
- 14 sitesBrazil
- Study dates
- 19 Sep 2025to 29 Sep 2029
- How long will I take part?
- 3 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: The study base consists of patients newly diagnosed with ovarian cancer across stages IA to IVB, and those with persistent or recurrent disease, diagnosed from January 2021 onwards.
Who may be able to join
- Patients ≥18 years old;
- Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021;
- Irrespective of histology
Who cannot join
- Borderline tumors;
- Pregnancy;
- Synchronous tumor or second primary in the last 5 years (except thyroid cancer and non-melanoma skin cancer);
Trial locations and contacts
14 sites in 1 country.
14 sites in 1 country
Brazil14 sites
Research Site
Barretos
Research Site
Belo Horizonte
Research Site
Brasília
Research Site
Curitiba
Research Site
Goiânia
Research Site
João Pessoa
Research Site
Natal
Research Site
Porto Alegre
Research Site
Recife
Research Site
Rio Branco
Research Site
Rio de Janeiro
Research Site
Salvador
Research Site
São Jose Dos Campos
Research Site
São Paulo
About this study
Official title: Ovarian Cancer Epidemiology and Care in Brazil: A Multicenter Perspective (OLIVIA Study) Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementation of quality parameters for the treatment of ovarian cancer in the country.
Read the detailed description
This study is an observational, bi-directional (prospective and retrospective) analytical study designed to assess the sociodemographic, clinical, and pathological characteristics of patients with ovarian cancer, stages IA to IVB, as well as those with persistent or recurrent disease. The study will include 250 patients who meet the eligibility criteria of being 18 years or older, with a diagnosis of ovarian cancer from January 2021, irrespective of histology, over a 1-year enrollment period across 20 participating sites.
Upon enrollment, baseline data will be collected, which includes sociodemographic details, clinical information, pathological findings, and genetic testing and counseling data. Follow-up data will be gathered at 12, 24, and 36 months to monitor treatment patterns and outcomes. These data collection points will allow for the evaluation of both short-term and long-term outcomes, providing valuable insights into the progression and management of ovarian cancer.
- Conditions
- Ovarian Cancer
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | patients newly diagnosed with ovarian cancer across stages IA to IVB, and those with persistent or recurrent disease, diagnosed from January 2021 onwards |
What is being measured
The primary outcome is the main question the study is designed to answer.
Description of socio-demographic characteristics
The study's findings could provide a basis for evaluating current practices in ovarian treatment and other characteristics about this disease.
By identifying strengths and weaknesses in existing care, the project aims to offer insights that may lead to the implementation of quality parameters for ovarian cancer treatment in the country.
No formal statistical comparisons are begin performed for the primary outcomes of this study.
Measured: Throught study a completation, an average of 3 years
Description of pathological characteristics
The study's findings could provide a basis for evaluating current practices in ovarian treatment and other characteristics about this disease.
By identifying strengths and weaknesses in existing care, the project aims to offer insights that may lead to the implementation of quality parameters for ovarian cancer treatment in the country.
No formal statistical comparisons are being performed for the primary outcomes of this study.
Measured: Throught study a completation, an average of 3 years
Description of treatment
The study's findings could provide a basis for evaluating current practices in ovarian treatment and other characteristics about this disease.
By identifying strengths and weaknesses in existing care, the project aims to offer insights that may lead to the implementation of quality parameters for ovarian cancer treatment in the country.
No formal statistical comparisons are being performed for the primary outcomes of this study.
Measured: Throught study a completation, an average of 3 years
Secondary outcomes (3)
Treatment interval of systemic therapy in metastatic disease
The study's findings could provide a basis for evaluating current practices in ovarian treatment and other characteristics about this disease.
By identifying strengths and weaknesses in existing care, the project aims to offer insights that may lead to the implementation of quality parameters for ovarian cancer treatment in the country.
No formal statistical comparisons are beign performed for the outcomes of this study.
Measured: Throught study a completation, an average of 3 years
Disease free-survival
The study's findings could provide a basis for evaluating current practices in ovarian treatment and other characteristics about this disease.
By identifying strengths and weaknesses in existing care, the project aims to offer insights that may lead to the implementation of quality parameters for ovarian cancer treatment in the country.
No formal statistical comparisons are beign performed for the outcomes of this study.
Measured: Throught study a completation, an average of 3 years
Time to next chemotherapy
The study's findings could provide a basis for evaluating current practices in ovarian treatment and other characteristics about this disease.
By identifying strengths and weaknesses in existing care, the project aims to offer insights that may lead to the implementation of quality parameters for ovarian cancer treatment in the country.
No formal statistical comparisons are beign performed for the outcomes of this study.
Measured: Throught study a completation, an average of 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2025
- Study start19 Sep 2025
- Primary completion29 Sep 2029 (estimated)
- Study completion29 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 256 participants (actual)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07167433
- Sponsor's protocol ID
- D133HR00051
- Acronym
- OLIVIA
- Status last verified
- Oct 2026
- First submitted
- 18 Aug 2025
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.